SOLO-Symbicort® in the treatment of persistent asthma in adolescents & adults

Study identifier:D5890L00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A comparison of Symbicort® Single inhaler Therapy (Symbicort® 200 Turbuhaler® 1 inhalation b.i.d. plus as needed) & conventional best practice for the treatment of persistent asthma in adolescents & adults–a 26-week, randomised, open-label, parallel group, multicentre study

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

Study drug

Budesonide/formoterol Turbuhaler

Sex

All

Actual Enrollment

1300

Study type

Interventional

Age

12 Years - Minutes

Date

Study Start Date: 01 May 2004

Primary Completion Date: 01 Oct 2005

Study Completion Date: 01 Oct 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Aldergrove, BC, Canada

Location

Research Site

Bolton, Ontario, Canada

Location

Research Site

Brampton, ON, Canada

Arms	Assigned Interventions

Documents available

http://www.astrazeneca.com/node/emailtriage.aspx
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=521&filename=CSR-D5890L00004.pdf
Download
CSR-D5890L00004.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Canada Information Center

1-800-668-6000

Investigators

Principal Investigator

AstraZeneca Rita Medical Science Director

AstraZeneca

SOLO-Symbicort® in the treatment of persistent asthma in adolescents & adults

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Documents available

http://www.astrazeneca.com/node/emailtriage.aspx

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=521&filename=CSR-D5890L00004.pdf

CSR-D5890L00004.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator